Given there are serious limitations to pharmaceutical cannabinoid medications, it’s clear that the problem lies in the insurance system that has yet to evolve alongside patients’ needs and medical science. There is a clear disconnect when insurance companies can cover synthetic cannabinoid drugs but can’t acknowledge the medicinal value of whole cannabis compounds. Then again, the issue circles back to the federal government.
New aggregated polls reveal that 55% of respondents believe marijuana is not dangerous, and a…
Every Croptober, growers waste time on folklore instead of physics. We break down the science…
Leafly's 2026 cannabis voter guide for the midterms is the only plan you need to…
Come along on an Emerald Triangle road trip with Lindsay MaHarry to see some of…
This month an Iowa church got what every sacramental-plant congregation dreams about: a path to…
The cannabis industry does not need another study, another tax revenue report, or another state-level…